# Aegle Therapeutics

> Aegle Therapeutics is a clinical-stage Boston-area biotech developing AGLE-102, a therapy built from extracellular vesicles - the tiny packages that stem cells use to send instructions to injured tissue. Instead of transplanting living cells, Aegle harvests the vesicles those cells release, loaded with proteins like collagen VII and the genetic material to make more. Its lead program targets recessive dystrophic epidermolysis bullosa, a rare and painful genetic skin-blistering disease with no cure, and it holds FDA Fast Track status with a first patient already dosed in a Phase 1/2a trial.

- **Founded:** 2014
- **Headquarters:** Woburn, Massachusetts, United States
- **Founders:** Shelley A. Hartman (Co-Founder & Chief Executive Officer), Evangelos V. Badiavas, Ph.D., M.D. (Founder, Inventor & Chief Scientific Officer)
- **Team size:** ~4 employees
- **Products:** AGLE-102, AGLE-102 for severe burns / scarring, EV platform for graft-versus-host disease (GvHD)
- **Notable:** FDA Fast Track designation granted to AGLE-102 for dystrophic epidermolysis bullosa (2020), First patient dosed in a Phase 1/2a clinical trial of AGLE-102 (2023-2024), Positive data reported for the first patient dosed with the EV therapy (January 2024)

## Products & services

- **AGLE-102** — A cell-free therapy composed of extracellular vesicles isolated from allogeneic bone marrow mesenchymal stem cells. It delivers proteins including collagen VII and biomolecules such as COL7A1 mRNA to reduce inflammation, modulate the immune system, and induce diseased cells to make their own collagen VII. Lead indication is recessive dystrophic epidermolysis bullosa; holds FDA Fast Track designation.
- **AGLE-102 for severe burns / scarring** — First-in-human proof-of-concept program applying the EV platform to burn wound healing and scar reduction (NCT05078385).
- **EV platform for graft-versus-host disease (GvHD)** — Preclinical program exploring MSC-derived extracellular vesicles for immune modulation in graft-versus-host disease.

## Achievements

- FDA Fast Track designation granted to AGLE-102 for dystrophic epidermolysis bullosa (2020)
- First patient dosed in a Phase 1/2a clinical trial of AGLE-102 (2023-2024)
- Positive data reported for the first patient dosed with the EV therapy (January 2024)
- Completed a $6.5M Series A financing (2020)
- Advanced a first-in-class cell-free extracellular-vesicle therapy from a university lab into human trials
- Named industry veteran Scott Braunstein, M.D. as Chairman of the Board (July 2025)

## Latest updates

- **2025-12** — Company reported additional financing activity (debt financing of approximately $455,695).
- **2025-07** — Named Scott Braunstein, M.D. as Chairman of the Board.
- **2024-08** — Announced first patient dosed in the Phase 1/2a trial of AGLE-102 in patients with dystrophic epidermolysis bullosa.
- **2024-03** — Phase 1/2a AGLE-102 trial in RDEB opened for enrollment.
- **2024-01** — Reported positive data for the first patient dosed with AGLE-102.

## Links

- Website: https://aegletherapeutics.com
- LinkedIn: https://www.linkedin.com/company/aegletherapeutics

---

Profile page: https://yespress.io/aegle-therapeutics
Published by YesPress — https://yespress.io
Last updated: 2026-08-20